These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 12355106)

  • 1. Strategic rethink for German biotechnology.
    Fernandes M; Miska D
    Nat Biotechnol; 2002 Oct; 20(10):970-1. PubMed ID: 12355106
    [No Abstract]   [Full Text] [Related]  

  • 2. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 3. The perils of subsidiarity.
    Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
    [No Abstract]   [Full Text] [Related]  

  • 4. Michigan's next wave of biopharmaceutical entrepreneurship.
    Kerppola R; van de Walle M; Surine S
    Nat Biotechnol; 2003 Sep; 21(9):1109-11. PubMed ID: 12949575
    [No Abstract]   [Full Text] [Related]  

  • 5. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 6. Marketing biotechnology with a Gallic flair.
    Jouanneau AC
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE36-7. PubMed ID: 12874977
    [No Abstract]   [Full Text] [Related]  

  • 7. The YIC factor.
    Nat Biotechnol; 2005 Oct; 23(10):1187. PubMed ID: 16211041
    [No Abstract]   [Full Text] [Related]  

  • 8. Taiwan: Biotech vision.
    Cyranoski D
    Nat Biotechnol; 2003 Apr; 21(4):463-4. PubMed ID: 12665831
    [No Abstract]   [Full Text] [Related]  

  • 9. India aims to become the main bioinformatics hub.
    Jayaraman KS; Louët S
    Nat Biotechnol; 2004 Aug; 22(8):933. PubMed ID: 15286632
    [No Abstract]   [Full Text] [Related]  

  • 10. Cash-strapped biotechs find financing alternative.
    Mitchell P
    Nat Biotechnol; 2004 Sep; 22(9):1057-8. PubMed ID: 15340452
    [No Abstract]   [Full Text] [Related]  

  • 11. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 12. Public biotechnology 2003-the numbers.
    Lähteenmäki R; Baker M
    Nat Biotechnol; 2004 Jun; 22(6):665-70. PubMed ID: 15175683
    [No Abstract]   [Full Text] [Related]  

  • 13. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 14. Chasing biotech, state by state--winners and losers.
    Wilan KH
    Nat Biotechnol; 2005 Feb; 23(2):175-9. PubMed ID: 15696143
    [No Abstract]   [Full Text] [Related]  

  • 15. Public biotechnology 2002--the numbers.
    Lähteenmäki R; DeFrancesco L
    Nat Biotechnol; 2003 Jun; 21(6):607-12. PubMed ID: 12776143
    [No Abstract]   [Full Text] [Related]  

  • 16. Investing in nanotechnology.
    Paull R; Wolfe J; Hébert P; Sinkula M
    Nat Biotechnol; 2003 Oct; 21(10):1144-7. PubMed ID: 14520393
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of private financing hobbles emerging biotech regions.
    Jia H; Jayarama KS; Astvatsaturyan M
    Nat Biotechnol; 2006 Jan; 24(1):7-9. PubMed ID: 16404378
    [No Abstract]   [Full Text] [Related]  

  • 18. When times get tough.
    Jong S
    Nat Biotechnol; 2009 Mar; 27(3):226-8. PubMed ID: 19274868
    [No Abstract]   [Full Text] [Related]  

  • 19. Academic entrepreneur--an oxymoron?
    Gee K
    Mol Interv; 2001 Oct; 1(4):186-8. PubMed ID: 14993339
    [No Abstract]   [Full Text] [Related]  

  • 20. The changing norms of the life sciences.
    Shorett P; Rabinow P; Billings PR
    Nat Biotechnol; 2003 Feb; 21(2):123-5. PubMed ID: 12560827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.